HSBC Holdings’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.1M | Buy |
37,256
+26,284
| +240% | +$1.71M | ﹤0.01% | 1503 |
|
|
2025
Q4 | $883K | Buy |
10,972
+8,893
| +428% | +$598K | ﹤0.01% | 2006 |
|
|
2025
Q3 | $101K | Sell |
2,079
-869
| -29% | -$53.8K | ﹤0.01% | 2591 |
|
|
2025
Q2 | $220K | Sell |
2,948
-2,220
| -43% | -$147K | ﹤0.01% | 2630 |
|
|
2025
Q1 | $327K | Sell |
5,168
-4,871
| -49% | -$331K | ﹤0.01% | 2327 |
|
|
2024
Q4 | $784K | Sell |
10,039
-1,825
| -15% | -$147K | ﹤0.01% | 1931 |
|
|
2024
Q3 | $944K | Buy |
11,864
+4,229
| +55% | +$342K | ﹤0.01% | 1725 |
|
|
2024
Q2 | $629K | Sell |
7,635
-40,228
| -84% | -$3.54M | ﹤0.01% | 1867 |
|
|
2024
Q1 | $4.08M | Buy |
47,863
+3,608
| +8% | +$283K | ﹤0.01% | 1175 |
|
|
2023
Q4 | $3.81M | Buy |
44,255
+34,443
| +351% | +$2.98M | ﹤0.01% | 1248 |
|
|
2023
Q3 | $887K | Sell |
9,812
-14,959
| -60% | -$1.34M | ﹤0.01% | 1766 |
|
|
2023
Q2 | $2.12M | Sell |
24,771
-9,584
| -28% | -$810K | ﹤0.01% | 1413 |
|
|
2023
Q1 | $2.84M | Sell |
34,355
-36,897
| -52% | -$2.99M | ﹤0.01% | 1361 |
|
|
2022
Q4 | $5.55M | Buy |
71,252
+16,869
| +31% | +$1.36M | 0.01% | 1205 |
|
|
2022
Q3 | $4.08M | Buy |
54,383
+10,761
| +25% | +$773K | 0.01% | 1266 |
|
|
2022
Q2 | $2.88M | Sell |
43,622
-1,673
| -4% | -$99K | ﹤0.01% | 1419 |
|
|
2022
Q1 | $2.86M | Buy |
45,295
+15,160
| +50% | +$824K | ﹤0.01% | 1438 |
|
|
2021
Q4 | $1.62M | Sell |
30,135
-28,626
| -49% | -$1.74M | ﹤0.01% | 1786 |
|
|
2021
Q3 | $4.15M | Buy |
58,761
+3,825
| +7% | +$241K | ﹤0.01% | 1222 |
|
|
2021
Q2 | $3.65M | Buy |
54,936
+47,888
| +679% | +$3.39M | ﹤0.01% | 1215 |
|
|
2021
Q1 | $786K | Buy |
7,048
+4,155
| +144% | +$514K | ﹤0.01% | 1723 |
|
|
2020
Q4 | $342K | Buy |
+2,893
| New | +$311K | ﹤0.01% | 2480 |
|
|
2020
Q1 | – | Sell |
-6,249
| Closed | -$718K | – | 2831 |
|
|
2019
Q4 | $718K | Sell |
6,249
-245
| -4% | -$29.6K | ﹤0.01% | 2024 |
|
|
2019
Q3 | $820K | Buy |
6,494
+2,248
| +53% | +$285K | ﹤0.01% | 2050 |
|
|
2019
Q2 | $511K | Sell |
4,246
-535
| -11% | -$52.6K | ﹤0.01% | 2054 |
|
|
2019
Q1 | $418K | Buy |
4,781
+2,292
| +92% | +$208K | ﹤0.01% | 2189 |
|
|
2018
Q4 | $249K | Sell |
2,489
-58
| -2% | -$6.09K | ﹤0.01% | 2378 |
|
|
2018
Q3 | $292K | Sell |
2,547
-251,850
| -99% | -$26.1M | ﹤0.01% | 2250 |
|
|
2018
Q2 | $22.8M | Buy |
254,397
+165,222
| +185% | +$14M | 0.04% | 445 |
|
|
2018
Q1 | $6.53M | Buy |
+89,175
| New | +$6.12M | 0.01% | 1008 |
|
|
2017
Q1 | – | Sell |
-11,081
| Closed | -$445K | – | 2305 |
|
|
2016
Q4 | $445K | Buy |
+11,081
| New | +$418K | ﹤0.01% | 1926 |
|
Other funds holding HAE
VPM
VCM
RRAM
HSBC Holdings's HAE Position: Q1 2026 in Review
HSBC Holdings increased its Haemonetics (HAE) stake by 240% in Q1 2026, buying an estimated $1.71M and bringing the position to 37,256 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1503.
HSBC Holdings first reported a position in HAE in Q4 2016 and has held it in 31 quarters since. The position peaked at $22.8M in Q2 2018. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- HSBC Holdings held 37,256 shares of Haemonetics worth $2.1M as of Q1 2026.
- HSBC Holdings bought 26,284 Haemonetics shares in Q1 2026, an estimated $1.71M.
- Haemonetics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1503 holding.
- HSBC Holdings first reported a position in Haemonetics in Q4 2016 and has held it in 31 quarters since.
- HSBC Holdings's Haemonetics position peaked at $22.8M in Q2 2018.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.